Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paulina Balcázar-Félix"'
Autor:
Jorge Hernández-Bello, José Javier Morales-Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle
Publikováno v:
Vaccines, Vol 9, Iss 9, p 1047 (2021)
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people
Externí odkaz:
https://doaj.org/article/98fbb9a0f1594a2f918dbadd1a20588c
Autor:
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Carlos Meza-López, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paola Carolina Torres-Hernández, Martín Bedolla-Barajas, Brenda De la O-Gómez, Paulina Balcázar-Félix, Jorge Hernández-Bello
Publikováno v:
Vaccines, Vol 9, Iss 7, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://doaj.org/article/9a7a8959a26a43a6b9770e5f6e4f8829
Autor:
Paulina Balcázar-Félix, José Javier Morales-Núñez, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Andrea Carolina Machado-Sulbaran, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández
Publikováno v:
Vaccines
Vaccines, Vol 9, Iss 1047, p 1047 (2021)
Vaccines; Volume 9; Issue 9; Pages: 1047
Vaccines, Vol 9, Iss 1047, p 1047 (2021)
Vaccines; Volume 9; Issue 9; Pages: 1047
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fefb485e1899ac4f399878b00f5f347c
https://pubmed.ncbi.nlm.nih.gov/34579284
https://pubmed.ncbi.nlm.nih.gov/34579284
Autor:
Jorge Hernández-Bello, Carlos Meza-López, Paola Carolina Torres-Hernández, Brenda De la O-Gómez, Martín Bedolla-Barajas, José Javier Morales-Núñez, José Francisco Muñoz-Valle, Lin-Fa Wang, Andrea Carolina Machado Sulbarán, Paulina Balcázar-Félix
Publikováno v:
Vaccines
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
Volume 9
Issue 7
Vaccines, Vol 9, Iss 742, p 742 (2021)
The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5fece3064d6436f9e7a7e883fa8f60
http://europepmc.org/articles/PMC8310237
http://europepmc.org/articles/PMC8310237